Mechanisms of aggressive Rhabdomyosarcoma.
侵袭性横纹肌肉瘤的机制。
基本信息
- 批准号:10560866
- 负责人:
- 金额:$ 54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAccountingAffectAggressive behaviorAllelesAnimal GeneticsAnimal ModelAntibodiesAutomobile DrivingBindingBinding SitesBiologicalCancer ModelCell modelCell surfaceCellsCessation of lifeChildhoodChildhood Soft Tissue SarcomaClustered Regularly Interspaced Short Palindromic RepeatsCombined Modality TherapyComplexDNA BindingDataDevelopmentDiagnosisDiseaseDoxycyclineDrug TargetingExhibitsGenesGenetic EngineeringGenetic TranscriptionGoalsGrantGrowthHeterogeneityHumanIn VitroKnock-inKnock-outMaintenanceMalignant NeoplasmsModelingMolecularMusMutateMutationOncogenicOperative Surgical ProceduresOutcomePIK3CA genePathway interactionsPatientsPharmaceutical PreparationsProductionPrognosisProteinsRadiation therapyRelapseReportingResistanceRhabdomyosarcomaRoleSkeletal MuscleSpecificityTestingTherapeuticUnited StatesWorkXenograft procedureZebrafishcancer stem cellcell typechemotherapyinnovationmalignant muscle neoplasmmultiple omicsmutantneoplastic cellnovelnucleasepatient derived xenograft modelprogramsrefractory cancersingle-cell RNA sequencingstem cell fatestem cell functiontargeted treatmenttherapeutic targettherapy resistanttranscription factortranslational impacttumortumor growth
项目摘要
ABSTRACT
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma in the United States and
displays features of skeletal muscle arrested at early stages of development. The aggressive MYOD1L122R
mutated spindle/sclerosing RMS subtype accounts for 10% of pediatric diagnoses and have an extremely poor
prognosis, even despite multi-modal treatment with surgery, radiation, and chemotherapy. The L122R
mutation is predicted to modulate the DNA binding specificity of the Myogenic Differentiation 1 (MYOD1)
transcription factor and regulates as of yet unknown transcriptional gene programs to elevate aggression and
treatment resistance. To date, a detailed molecular understanding of how MYOD1L122R affects the genesis of
RMS, its progression and drives therapy resistance is unknown. No cellular or molecular mechanistic studies of
MYOD1L122R in RMS have been reported, no tractable genetically-engineered animal models have been
developed, nor is it known if MYOD1L122R is required for continued human tumor growth or if it is rather a
modifier of disease aggression, therapy resistance, or cancer stem cells (CSCs). The long-term goal and
objective of our studies is to identify new molecular mechanisms and drug targets in MYOD1L122R mutant RMS
that regulate aggression, therapy resistance, and CSCs. Our central hypothesis is that MYOD1L122R is a neo-
morphic transcription factor that regulates pathways required for tumor maintenance and the production of
therapy-resistant CSCs. The rationale and feasibility of our approach lies in our group’s recent discovery of
molecularly distinct CSCs in MYOD1L122R mutant RMS, robust data showing that CSCs pathways and numbers
are increased in isogenic knock-in and doxycycline-inducible MYOD1L122R RMS human cell models, and
development of a new zebrafish model of MYOD1L122R-induced RMS that has elevated numbers of tumor-
propagating cells. Aim 1 will assess roles for MYOD1L122R in enhancing tumor onset, growth, CSCs, and
therapy resistance. Aim 1a will innovate new MYOD1L122R mutant RMS zebrafish models, testing the
hypothesis that MYOD1L122R is itself not oncogenic, but drives elevated aggression only when complexed with
other oncogenic drivers including activating mutations in RAS and PIK3CA. We also hypothesize that
MYOD1L122R acts in part by increasing the overall fraction of tumor-propagating cells. Aim 1b will extend these
findings to human RMS, testing the hypothesis that MYOD1L122R is required for continued tumor maintenance
and regulates cell states including the production of therapy-resistance CSCs. Aim 2 will uncover MYOD1L122R
regulated transcriptional targets, pathways, and mechanisms in RMS, testing the hypothesis that MYOD1L122R
alters the DNA binding site specificity and transcriptionally regulates a novel set of genes to promote elevated
RMS aggression, therapy resistance, and cancer stem cell fate. This work will have a positive translational
impact by defining new pathways to kill MYOD1L122R mutant RMS, including those that target therapy-resistant
CSCs, and identifying potential therapeutic targets that are likely shared across RMS subtypes.
摘要
横纹肌肉瘤(RMS)是美国最常见的儿科软组织肉瘤,
显示出骨骼肌在早期发育阶段停止的特征。具有侵略性的MYOD 1 L122 R
突变的梭形/硬化型RMS亚型占儿科诊断的10%,
即使采用手术、放疗和化疗等多模式治疗,预后也是如此。L122R
预测突变调节肌原性分化1(MYOD 1)的DNA结合特异性
转录因子,并调节未知的转录基因程序,以提高侵略性,
治疗阻力迄今为止,关于MYOD 1 L122 R如何影响MYOD 1 L122基因的发生的详细分子理解,
RMS、其进展和驱动治疗抗性是未知的。没有细胞或分子机制的研究
MYOD 1 L122 R在RMS中的表达已有报道,但尚未建立易于处理的基因工程动物模型。
目前还不清楚MYOD 1 L122 R是否是人类肿瘤持续生长所必需的,或者它是否是一种肿瘤抑制剂。
疾病侵袭、治疗抗性或癌症干细胞(CSC)的修饰剂。长期目标和
我们的研究目的是确定MYOD 1 L122 R突变型RMS的新分子机制和药物靶点
调节攻击性、治疗抵抗和CSC。我们的中心假设是MYOD 1 L122 R是一个新的,
一种调节肿瘤维持和产生所需途径的形态转录因子
治疗抗性CSC。我们方法的合理性和可行性在于我们小组最近发现,
MYOD 1 L122 R突变型RMS中分子上不同的CSC,稳健的数据表明,
在同基因敲入和多西环素诱导的MYOD 1 L122 R RMS人细胞模型中增加,和
开发了一种新的MYOD 1 L122 R诱导的RMS斑马鱼模型,该模型的肿瘤数量增加,
繁殖细胞目的1将评估MYOD 1 L122 R在增强肿瘤发生、生长、CSC和肿瘤生长中的作用。
治疗抵抗Aim 1a将创新新的MYOD 1 L122 R突变体RMS斑马鱼模型,测试
MYOD 1 L122 R本身不是致癌的,但只有当与MYOD 1 L122 R复合时,
其他致癌驱动因素,包括RAS和PIK 3CA中的激活突变。我们还假设,
MYOD 1 L122 R部分通过增加肿瘤增殖细胞的总体分数起作用。目标1b将扩展这些
研究结果对人类RMS,测试MYOD 1 L122 R是持续肿瘤维持所需的假设
并调节细胞状态,包括治疗抗性CSC的产生。目标2将揭开MYOD 1 L122 R
调节RMS中的转录靶点、途径和机制,检验MYOD 1 L122 R
改变了DNA结合位点的特异性,并在转录上调节一组新的基因,
RMS侵略性,治疗抗性和癌症干细胞命运。这项工作将有积极的翻译
通过定义新的途径杀死MYOD 1 L122 R突变型RMS,包括那些靶向治疗耐药的RMS,
CSC,并确定可能在RMS亚型之间共享的潜在治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Michael Langenau其他文献
David Michael Langenau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Michael Langenau', 18)}}的其他基金
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis
横纹肌肉瘤细胞状态、癌症干细胞和转移的致癌驱动因素
- 批准号:
10658091 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Developing preclinical xenograft models in zebrafish.
在斑马鱼中开发临床前异种移植模型。
- 批准号:
10334672 - 财政年份:2022
- 资助金额:
$ 54万 - 项目类别:
Developing preclinical xenograft models in zebrafish.
在斑马鱼中开发临床前异种移植模型。
- 批准号:
10578692 - 财政年份:2022
- 资助金额:
$ 54万 - 项目类别:
Stem cell self-renewal programs in rhabdomyosarcoma
横纹肌肉瘤的干细胞自我更新计划
- 批准号:
10321242 - 财政年份:2018
- 资助金额:
$ 54万 - 项目类别:
New models and therapeutic approaches in alveolar rhabdomyosarcoma
肺泡横纹肌肉瘤的新模型和治疗方法
- 批准号:
9899960 - 财政年份:2018
- 资助金额:
$ 54万 - 项目类别:
New models and therapeutic approaches in alveolar rhabdomyosarcoma
肺泡横纹肌肉瘤的新模型和治疗方法
- 批准号:
10375518 - 财政年份:2018
- 资助金额:
$ 54万 - 项目类别:
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia
T细胞急性淋巴细胞白血病的致癌途径和治疗靶点
- 批准号:
10225314 - 财政年份:2017
- 资助金额:
$ 54万 - 项目类别:
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia
T细胞急性淋巴细胞白血病的致癌途径和治疗靶点
- 批准号:
9383339 - 财政年份:2017
- 资助金额:
$ 54万 - 项目类别:
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia
T细胞急性淋巴细胞白血病的致癌途径和治疗靶点
- 批准号:
9751256 - 财政年份:2017
- 资助金额:
$ 54万 - 项目类别:
Immune Compromised Zebrafish for Cell Transplantation
用于细胞移植的免疫受损斑马鱼
- 批准号:
10454455 - 财政年份:2013
- 资助金额:
$ 54万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 54万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 54万 - 项目类别: